Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News OptiNose Inc OPTN

Healthcare
OptiNose, Inc. is a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing its Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and... see more

Recent & Breaking News (NDAQ:OPTN)

Optinose to Present at the Cantor Virtual Global Healthcare Conference

GlobeNewswire September 22, 2021

Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire August 25, 2021

Optinose Reports Second Quarter 2021 Financial Results and Recent Operational Highlights

GlobeNewswire August 11, 2021

Optinose Completes Patient Recruitment in Pivotal Trial for XHANCE in Chronic Sinusitis

GlobeNewswire July 30, 2021

Optinose Announces Preliminary Second Quarter 2021 XHANCE Net Revenue of $18.4 Million

GlobeNewswire July 28, 2021

Optinose Technology Inventor Per Djupesland Named Winner of European Inventor Award 2021 for Industry

GlobeNewswire June 24, 2021

Experts Issue New Treatment Algorithm for Chronic Rhinosinusitis with Nasal Polyps That Highlights Role of XHANCE® In Stepwise Care

PR Newswire June 2, 2021

Optinose to Present at the Jefferies Virtual Healthcare Conference

GlobeNewswire June 1, 2021

Optinose Reports First Quarter 2021 Financial Results and Operational Updates

GlobeNewswire May 5, 2021

Optinose Announces Reporting Date for First Quarter 2021 Financial Results and Upcoming Healthcare Conference Presentation

GlobeNewswire April 28, 2021

New Harris Survey Reveals Chronic Nasal Congestion Is Surprisingly Widespread: Nearly 1 in 4 Americans With Nasal Congestion Experience Symptoms Almost Every Day

PR Newswire April 27, 2021

Optinose to Present at the Needham Virtual Healthcare Conference

GlobeNewswire April 12, 2021

Optinose Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights

GlobeNewswire March 3, 2021

Optinose Announces Reporting Date for Fourth Quarter 2020 Financial Results

GlobeNewswire February 17, 2021

Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 25, 2021

Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 21, 2020

Optinose Announces Changes to Board of Directors

GlobeNewswire December 1, 2020

Optinose Reports Third Quarter 2020 Financial Results and Recent Operational Highlights

GlobeNewswire November 5, 2020

Optinose Announces Preliminary Third Quarter 2020 XHANCE Net Revenue of $15.4 Million

GlobeNewswire October 22, 2020

New Peer-Reviewed Data Highlight the Benefits of XHANCE in Patients Who Remain Symptomatic After Treatment with Standard Nasal Steroid Sprays

PR Newswire September 29, 2020